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Abstract
MicroRNAs (miRNAs) are short (,22 nt) non-coding regulatory RNAs that control gene expression at the post-transcriptional
level. Deregulation of miRNA expression has been discovered in a wide variety of tumours and it is now clear that they
contribute to cancer development and progression. Cervical cancer is one of the most common cancers in women
worldwide and there is a strong need for a non-invasive, fast and efficient method to diagnose the disease. We investigated
miRNA expression profiles in cervical cancer using a microarray platform containing probes for mature miRNAs. We have
evaluated miRNA expression profiles of a heterogeneous set of cervical tissues from 25 different patients. This set included
19 normal cervical tissues, 4 squamous cell carcinoma, 5 high-grade squamous intraepithelial lesion (HSIL) and 9 low-grade
squamous intraepithelial lesion (LSIL) samples. We observed high variability in miRNA expression especially among normal
cervical samples, which prevented us from obtaining a unique miRNA expression signature for this tumour type. However,
deregulated miRNAs were identified in malignant and pre-malignant cervical tissues after tackling the high expression
variability observed. We were also able to identify putative target genes of relevant candidate miRNAs. Our results show
that miRNA expression shows natural variability among human samples, which complicates miRNA data profiling analysis.
However, such expression noise can be filtered and does not prevent the identification of deregulated miRNAs that play a
role in the malignant transformation of cervical squamous cells. Deregulated miRNAs highlight new candidate gene targets
allowing for a better understanding of the molecular mechanism underlying the development of this tumour type.
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Introduction
Cervical cancer is the second most common cause of cancer-
related deaths in women worldwide, incidence and mortality are,
however, decreasing due to the implementation of Cervical
Cancer Screening Programmes by cytological smear testing [1].
This tumour type evolves from pre-existing non-invasive pre-
malignant lesions referred to as squamous intraepithelial lesions
(SILs) or cervical intraepithelial lesions (CINs). These lesions are
classified histologically on the basis of atypia of epithelial cells that
progressively extend from the lower parabasal layers of the
squamous epithelium up to the whole thickness of the epithelium,
depending on the grade [2]. CINI and low-grade SIL (LSIL)
correspond to mild dysplasia, CINII to moderate dysplasia and
CINIII to both severe dysplasia and carcinoma in situ. HSIL
represents the combination of CINII and CINIII. Persistent
infection with high-risk types of human papillomavirus (HPV) is
the causal agent for cervical neoplasia [2]. This virus contributes to
neoplastic progression through the action of two viral oncoproteins
E6 and E7, which interfere with critical cell cycle pathways,
tumour protein p53 and retinoblastoma protein [3]. Nevertheless,
evidence suggests that HPV infection alone is insufficient to induce
malignant changes and other host genetic variations are important
in the development of cervical cancer [2].
MicroRNAs (miRNAs) are a class of evolutionary conserved
non-coding RNAs that regulate stability and translation efficiency
of target mRNAs [4] and have a direct impact on cancer
development [5]. These RNAs are 19 to 25 nt long and are
cleaved from 70 to 100 nt hairpin pre-miRNA precursors. The
precursors are cleaved by cytoplasmic RNase III Dicer into
,22 nt miRNA duplex: one strand (miRNA*) of the short-lived
duplex is degraded, whereas the other strand, which serves as
mature miRNA, is incorporated into the RNA-induced silencing
complex (RISC) and drives the selection of target miRNAs
containing antisense sequences [4]. They are likely to control
expression of thousands of genes, suggesting that they play
fundamental global roles in human biology, including develop-
ment, differentiation, apoptosis, metabolism, viral infection and
cancer [4].
Comparison between human cancer and their normal tissues
counterparts have revealed distinct miRNA expression profiles.
Several studies have shown that miRNAs are aberrantly expressed
or mutated in tumours and recent data strongly suggests that
miRNA profiling is more robust than mRNA profiling in tumour
classification [6,7]. Moreover, a growing number of miRNAs have
been implicated in promoting or suppressing tumorigenesis in a
variety of tissues [8–10], suggesting that they may play a role as a
novel class of oncogenes or tumour suppressor genes. This is
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present in more than half of all chronic lymphocytic leukemias
(CLL) results in loss of miR-15a and miR-16-1 genes [11]. And the
mir-17/92 cluster cooperates with the oncogene Myc during
tumour development in a mouse model [12], while miR-372 and
miR-373 cooperate with the RAS oncogene in an in vitro assay [13].
Finally, more than 50% of miRNA genes are located in
chromosome domains that are genetically altered in human
cancer [14].
The role of miRNAs in cervical cancer is still poorly
understood, however various studies have already been carried
out. Lui et al. have characterized the profiles of miRNAs and
other small RNA segments in six human cervical cell lines and
five normal cervical samples using a direct sequencing method
[15]. They found reduced expression of miR-143 and increased
expression of miR-21 in 29 matched pairs of human cervical
cancer and normal cervical specimens [15]. Another study
showed that miRNA profiles in cervical squamous cell carcinoma
depend on Drosha, which is an RNase III enzyme involved in the
miRNA biogenesis pathway [16]. Martinez and co-workers have
demonstrated that HPV alter the expression of miRNAs in
cervical carcinoma cell lines [17]. In a fourth study, 10 early stage
invasive squamous cell carcinomas (ISSC) and 10 normal cervical
squamous epithelial biopsies were profiled for miRNA misexpres-
sion using TaqMan real-time quantitative PCR [18]. This study
identified 68 up-regulated and 2 down-regulated miRNAs
between the ISCCs and normal epithelial tissues, with miR-
199s, miR-9, miR-199a*, miR-199a, miR-199b, miR-145, miR-
133a, miR-133b, miR-214 and miR-127 being among the
miRNAs most overexpressed. By contrast, only two of the
miRNAs, miR-149 and miR-203 showed significant down-
regulation [18]. A study analyzing eight cervical cancer cell
lines, two HPV16+ W12 subclones [19] and five age-matched
normal cervix and cervical cancer tissues was also reported [20].
The authors showed that miR-126, miR-143 and miR-145 were
down-regulated and miR-15b, miR-16, mi-146 and miR-155
were up-regulated. Their data also indicated that decreased miR-
143 and miR-145 expression and increased miR-146a expression
are relevant for cervical carcinogenesis. Finally, Hu and co-
workers have recently identified miR-200a and miR-9 as
predictors of patient survival in cervical carcinoma [21]. These
studies were unable to clarify the role of miRNAs in cervical
cancer due to inconsistency in miRNA expression between them,
which may be due to differences in the high-throughput platforms
and methods used in different laboratories or due to differences
among the cancer population. Also, a full characterization of the
complex relationship between miRNAs and their target mRNAs
in cervical malignant transformation has not yet been carried out.
We present the results of miRNA expression profiling in cervical
squamous cell carcinomas (SCC), low and high-grade intraepithe-
lial cervical lesions and normal cervical epithelial tissues. As in
other studies, we have observed high expression variability
between samples, especially among normal cervical samples,
which did not allow us to obtain a unique miRNA expression
signature for this tumour type. We demonstrate using Taqman
miRNA real-time PCR quantification method that such variability
is biological rather than technical. We have tackled such biological
variability by pooling the RNAs from the normal samples, which
averaged miRNAs levels in the controls, and we demonstrate that
this methodology is sufficiently robust to identify miRNAs that
were deregulated between malignant, pre-malignant and normal
cervical tissues, which may be involved in cervical carcinogenesis.
We also identify possible gene targets of relevant candidate
miRNAs.
Results
High variability of miRNA expression in cervical tissues
We used a miRNA microarray spotted in house to analyze
miRNA expression in four cervical squamous cell carcinomas
(SCC), five high-grade intraepithelial lesions, nine low-grade
intraepithelial lesions and 19 normal cervical tissues; a total of
25 biologically independent samples (Table 1). These tissues were
initially snap-frozen in liquid nitrogen and then stored at 280uC
until used. A pool of four commercial RNAs from normal cervix
(Ambion) was used as common reference. Following RNA
hybridization and array analysis, samples were clustered according
to their miRNA expression profile using the hierarchical clustering
algorithm of the MeV 4.0.01 software package (Figure 1A) but,
surprisingly, the generated tree showed no clear distinction of
samples regarding their histological classification (Figure 1B,
coloured top bar). Also, we could not identify miRNAs with
significant down- or up-regulation in pre- and malignant samples
versus normal cervix (Figure 1B, heat map clusters zoomed-in).
We were not able to find differentially expressed miRNAs between
all samples, according to their histological classification. The
overall heat map did not show clusters with different miRNA
expression pattern between normal, pre- and malignant samples
(Figure 1A).
In order to validate or reject the microarray data and to ensure
that the variability observed among samples was not technical we
carried out a Taqman miRNA quantitative real-time PCR analysis
of five miRNAs of three cervical carcinoma, six atypical dysplasia
(CINIII, n=3; CINI, n=3) and 1 normal pooled samples. Each
miRNA was quantified in each sample and its expression level was
normalized to that of the RNU6 and to commercial normal cervix
RNA, which was used as reference. The miRNA expression
patterns from normal to cervical cancer were consistent between
the microarray and Taqman measurements (Figure 2A). This
confirmed that the variability found in the miRNA profiles was
biological rather than technical. In addition, we also performed
Taqman miRNA assay in a HeLa cell line (Invitrogen) and we
compared it with cervical carcinoma samples data (Figure 2B).
In an attempt to overcome or minimize such variability in the
normal samples we have prepared a RNA pool containing equal
amounts of total RNAs extracted from the normal cervical biopsies
and we hybridized it on the miRNA arrays as described for the
other samples, and performed Taqman miRNA assay. Thus, we
were able to reduce sample variation due to the presence/absence
of HPV and patient’s age, this method allowed us to dilute inter-
individual variability. To assess whether this strategy was effective
we have performed unsupervised hierarchical clustering of the
miRNAs that were differentially expressed between samples (21
miRNAs). Three groups representing: normal samples (N); low-
grade intraepithelial lesion (L) (exceptions were samples L1 and
L2) and high-grade intraepithelial lesion (H)/cervical carcinoma
(C), were then visible in the cluster analysis (Figure 3).
Differentially expressed miRNAs in cervical cancer
Using the methodology described above we were able to identify
21 miRNAs with statistically significant differential expression
between the pool of normal samples (n=4), 14 atypical dysplasia
(CINI, n=9 and CIN III, n=5) and 4 cervical carcinoma (p,0.05).
Eight miRNAsexhibited relative decreased expressionwithtransition
from normal cervix to atypical dysplasia to cancer (miR-26a, miR-
143, miR-145, miR-99a, miR-203,m i R - 5 1 3 ,m i R - 2 9 a ,m i R - 1 9 9 a )
(Figure 4A). Six miRNAs displayed relative decreased expression in
the transition from normal cervix to atypical dysplasia and increased
expression in the transition from atypical dysplasia to cervical
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27a and miR-142-5p (Figure 4B). Two miRNAs exhibited relative
increased expression in the transition from normal cervix to atypical
dysplasia and decreased expression in the transition from atypical
dysplasia to cervical carcinoma, namely miR-522* and miR-512-3p
(Figure 4C). Five miRNAs displayed relative increased expression in
thetransitionfromnormalcervixtoatypicaldysplasia tocancer, these
were miR-148a, miR-302b, miR-10a, miR-196a and miR-132
(Figure 4 D).
Interestingly, several of these miRNAs are associated with fragile
sites (FRAs) (Table S1). For example, miR-142-5p is located in
FRA17B, while miR-196a and miR-29a are located in FRA12A and
FRA7H, respectively. Furthermore, many of these miRNAs are
located in chromosomal regions that are frequently deleted or
amplified in several malignancies (Table S1). MicroRNA-143 and
miR-145 are located in a region, which is deleted in prostate cancer,
whereas miR-205 is located in the 12q14.1 region, which is amplified
in lung cancer. Therefore, these data strongly suggest that miRNAs
identified in this study are indeed relevant to cervical cancer.
Predicted gene targets of miRNAs
MicroRNAs can regulate a large number of target genes and
several databases based on various algorithms are available for
predicting the targets of selected miRNAs. TargetScan 4.2, PicTar
and miRanda were used to predict gene targets of 21 differentially
expressed miRNAs with transition from normal to atypical
dysplasia to cervical carcinoma (Table S2). The predictive targets
were considered if they were predicted by at least two of the
algorithms. To explore the biological significance of the predicted
targets of the 21 deregulated miRNAs identified, we used
Ingenuity Systems pathway analysis software (Table 2 and table
S3). Reassuringly, the analysis identified ‘‘cancer’’ as the main
disease associated with expression of those miRNAs. Cell death,
cellular movement, cellular growth and proliferation and gene
expression were the main biological processes related with these
expression patterns. Regarding the canonical pathways, there was
less consistency, with Wnt/b-catenin signaling found three times
(miR-145, miR-199a and miR-132). ERK/MAPK signaling (miR-
203), PTEN signaling (miR-27a), VEGF signalling (miR-10a), p53
signaling (miR-205) and apoptosis signalling (miR-512-3p) were
found once (Table 2 and table S3). These data suggest that while
the general pathways are related to cancer, the specific molecular
pathways targeted by the deregulated miRNAs are variable and
depend on each miRNA. This again points to high level of
complexity of miRNA target selection and regulation.
Finally, we have identified a number of down-regulated
miRNAs whose targets are up-regulated in cancer, including the
oncogenic protein KRAS and MYCN, mitogen-activated protein
(MAP) kinases and the anti-apoptotic proteins BCL2, BCL2L2
and MCL-1 among others (see table S2). These data provide
further support for a pivotal role of the miRNAs identified in this
study in cervical cancer.
Discussion
Previous studies support the hypothesis that specific miRNA
expression signatures in various types of human cancers can be
associated with diagnosis, prognosis and response to chemotherapy
[22]. Since specific miRNAs may have crucial roles in cancer
pathogenesis and progression through their effects on various
molecular pathways, a better understanding of miRNA expression
in human cancer may reveal novel molecular pathways or novel
mechanisms of activation of known pathways. Interestingly,
several miRNAs are frequently located in cancer-related genomic
regions, which include minimal regions of amplification, loss of
heterozygosity, fragile sites, common breakpoint regions in or near
oncogenes or tumour suppressor genes and at or near HPV
integration sites [14].
This study demonstrated that miRNAs are aberrantly expressed
in human cervical cancer and cervical pre-neoplasic lesions. The
overall miRNA expression profile could not clearly separate
normal, pre-neoplasic and cancer tissues probably due to the high
variability among normal cervical samples. One reason for this
variability could be the presence of the HPV in normal samples
since these samples were collected in normal epithelium adjacent
to the lesion and HPV detection by PCR showed both HPV
presence and absence in normal samples (data not shown).
Martinez and co-workers showed that HPV type 16 and 18 can
alter miRNA expression in cases where the virus is both integrated
and epissomal [17]. This could explain the variability observed in
normal cervical tissues since the commercial RNA from normal
cervix used as common reference was HPV negative. The
confirmation of the differential expression pattern obtained by
microarray analysis of five miRNAs by Taqman qRT-PCR
excluded the possibility that the high variability among samples
was technical. MicroRNA expression measurement in HeLa cells
by Taqman qRT-PCR compared with cervical carcinoma tissues
Table 1. Clinicopathologic background of 25 patients used in
this study.
Descriptive characteristics of patients
Patient # Age Lesion type
FIGO
stage
Human
Papillo-
mavirus Microarray
1 32 LSIL/CINI + L2, N9
2 49 HSIL/CIN II 2 H3, N8
3 44 LSIL/CIN I + L1, N16
4 51 LSIL/CINI + L10
5 44 LSIL/CIN I + L5, N4
6 30 LSIL/CIN I N7
7 40 HSIL/CIN II + H1
8 25 LSIL/CIN I + L6, N1
9 46 LSIL N6
10 33 LSIL/CIN I 2 L11, N17
11 35 LSIL/CIN I N5
12 25 HSIL/CIN III + H4, N2
13 50 SCC IA1 + C3, N3
14 28 HSIL/CIN III + H5
15 21 HSIL/CIN III + H6, N12
16 39 HSIL/CINIII/CIS + H7
17 33 LSIL/CIN I + L7, N13
18 27 HSIL/CIN III 2 H2, N10
19 44 SCC 0 + C4, N11
20 27 LSIL/CIN I + L8, N14
21 30 LSIL/CIN I + L9, N15
22 47 SCC IB1 + C5
23 29 No lesion N18
24 28 No lesion N19
25 30 SCC IIB + C6
doi:10.1371/journal.pone.0011780.t001
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PLoS ONE | www.plosone.org 3 July 2010 | Volume 5 | Issue 7 | e11780Figure 1. Cluster analysis of cervical samples. A) Tree generated by unsupervised hierarchical clustering (Pearson correlation, average linkage)
of 25 cervical samples (columns) and 126 miRNAs (rows). B) Zoom-in of some of the miRNAs showing that samples were not grouped according to
their histological classification. The profiles identified are relative to commercial RNA from normal cervix. Blue, carcinoma; Yellow, High-grade
Intraepithelial Lesion (HSIL); Red, Low-grade Intraepithelial Lesion (LSIL); Green, Adjacent normal tissue. Colours in the heatmap indicate: green, lower
expression compared to the mean (zero); black, expression equal to the mean; gray, absent data points and red, higher expression compared to the
mean.
doi:10.1371/journal.pone.0011780.g001
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of miR-10a, although the values of fold induction were not the
same. This could be due to biological differences between the
immortalized cell line and fresh biopsies. By pooling normal
cervical samples to reduce the variability observed we were able to
separate normal, pre-neoplasic and cancer samples and identified
a number of miRNAs whose expression was altered in human
cervical cancer and pre-neoplasic samples. Therefore, a degree of
caution is required when carrying out miRNA profiling using
human biopsies. Indeed, natural genetic variation in the human
population, latent viral infections, aging and health problems may
be important sources of biological variation in the expression
profiles. Such problems may explain the inconsistencies in miRNA
profiles described in the literature (Table 3) and may contribute to
erroneous interpretations of the data and affect future therapeutic
strategies based on RNAi.
miRNAs down-regulated between normal cervix and pre-
and neoplasic samples
At least eight miRNAs showed significant down-regulation
between normal cervical samples and the pre-neoplasic and
neoplasic samples, namely miR-143, miR-145, miR-99a, miR-
26a, miR-203, miR-513, miR-29a and miR-199a. The abundance
of miR-143 and miR-145 was sharply reduced between the
normal cervical samples and cervical pre-neoplasic and cancer
tissues, which is in agreement with previous cervical cancer studies
[15,20]. Similarly, expression of miR-143 and miR-145 was
reduced in different tumour types, e.g., colorectal tumours [23],
breast, prostate and B cell lymphoma [24,25], suggesting that
those miRNAs may have a suppressor role in a wide range of
tumours. Previous studies also showed that miR-143 and miR-145,
which are expressed from the same precursor [26], showed
reduced expression in HPV-induced pre-neoplasic lesions suggest-
ing that they might be involved in cervical carcinogenesis. These
miRNAs are located in sites of frequent chromosomal instability
[14] resulting in loss- or gain-of-function of their activity, which
seems to be a key event in the genesis of a variety of cancers.
Among the down-regulated miRNAs was miR-199a, which is also
down-regulated in hepatocellular carcinoma [27] and ovarian
cancer [28]. This contradicts data from a recent cervical cancer
study, which showed that miR-199a was up-regulated in early
stage invasive squamous cell carcinomas [18]. The same study
showed that an anti-miR-199a inhibits cell growth, suggesting that
miR-199a can promote cell proliferation. These discrepancies may
Figure 3. Unsupervised hierarchical clustering of 21 miRNAs whose expression was deregulated. (Pearson correlation, average linkage).
The 24 cervical samples are indicated in the columns and 21 miRNAs are indicated in the rows. C, carcinoma; H, High-grade Intraepithelial Lesion; L,
Low-grade Intraepithelial Lesion; N, Adjacent normal tissue pool. The colour scale at the top of the panel represents the degree of expression. Green
indicates lower expression than the mean (zero), black indicates expression equal to the mean, gray indicates absent data points, and red indicates
higher expression compared to the mean. Green represents the group of normal samples, red represents the low-grade intraepithelial lesion group,
blue represents the high-grade intraepithelial lesion/cervical carcinoma group and yellow represents the high-grade intraepithelial lesion group (with
exception of L1).
doi:10.1371/journal.pone.0011780.g003
Figure 2. Expression of 5 miRNAs quantified by Taqman quantitative real-time PCR assay. A) Comparison of miRNA expression levels
obtained by spotted arrays and Taqman qRT-PCR analysis of 3 cervical cancers (black), 3 High-grade Intraepithelial Lesions (diagonal), 3 Low-grade
Intraepithelial lesions (dark grey) and 1 normal pooled sample (light grey) compared with normal cervix reference. B) miRNA expression
measurement in HeLa cells and cervical cancers by Taqman qRT-PCR compared with normal cervix reference. The abundance of each miRNA in a total
RNA sample was normalized to the level of the RNU6 in the same sample.
doi:10.1371/journal.pone.0011780.g002
Cervical Cancer MicroRNAs
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of miRNA expression while Lee and co-workers used the TaqMan
miRNA assay [18]. Also, the samples that we have used as normal
control were different from those used by Lee and colleagues and
the control sample could also have influenced the outcome of the
miRNA profiling analysis [29]. Similar discrepancies were also
observed for miR-26a and miR-29a, which were down-regulated
in our study and up-regulated in the study of Lee and co-workers
[18] (Figure 3). Further source of miRNA expression heterogeneity
in cervical cancer is related to the cellular levels of Drosha, at least
in cervical squamous cell carcinoma [16]. We have not quantified
Drosha levels by western blot analysis, but this may be an
important variable to consider in future studies.
The microarray data of miR-26a showed that its expression was
decreased in pre-neoplasic and cancer in comparison with normal
cervical samples. Interestingly, miR-26a-1 is located in sites of
frequent chromosomal instability [14] and it is down-regulated in
many other tumour types, namely in thyroid anaplastic [30] and
breast carcinomas [31]. miR-29a is located in the fragile site
FRA7H, is deleted in prostate cancer [32] and is down-regulated
in serous ovarian cancer [33]. We also have found that miR-29a
can potentially target BCL2L2, VEGFA and CDK6, which are
involved in cancer initiation and progression (see table S2).
Therefore, these miRNAs may be involved in the cervical
carcinogenesis mechanism. Other down-regulated miRNAs in-
cluded miR-99a, which is deleted in the lung cancer cell line
MA17 [34] and in serous ovarian cancer [33] and miR-203 whose
gene is deleted in nasopharyngeal carcinoma [35] and is down-
regulated in cervical cancer [18]. Finally, miR-513 which targets
the oncogene KRAS, the c-myc binding protein (MYCBP),
Figure 4. Scatter-plots representing the relative expression levels of 21 miRNAs. The relative expression of the 21 miRNAs that were
deregulated are represented for normal cervix (red), CINI-cervical intraepithelial lesion grade I (green), CINIII-cervical intraepithelial lesion grade III
(blue) and squamous cervical carcinoma (black) samples. A) 8 miRNAs that showed relative decrease in expression in the transition from normal
cervix through premalignant dysplasia to cancer. B) 6 miRNAs that showed relative decreased expression in the transition from normal cervix to
premalignant dysplasia, but returning to normal cervix expression levels in cancer. C) 2 miRNAs that showed relative increased expression in the
transition from normal cervix to premalignant dysplasia, returing to normal cervix levels in cancer. D) 5 miRNAs showed relative increase in miRNA
expression levels in the transition from normal cervix through premalignant dysplasia to cancer.
doi:10.1371/journal.pone.0011780.g004
Table 2. Ingenuity analysis of miRNA predictive target genes.
Disease
Molecular and
Cellular Function Physiological System Canonical Pathway
miR-143 Cancer Cellular Growth and Proliferation Connective Tissue Development
and Function
PPAR Signaling
miR-145 Cancer Cellular Movement Tissue Development IGF-1 Signaling
miR-99a Cancer Cell Death Embryonic Development Wnt/b-catenin Signaling
miR-26a Cancer Cellular Growth and Proliferation Tissue Morphology Synaptic Long Term Potentiation
miR-203 Cancer Gene Expression Nervous System Development
and Function
ERK/MAPK Signaling
miR-513-5p Cancer Gene Expression Hematological System Development
and Function
Thrombopoietin Signaling
miR-29a Cancer Gene Expression Tissue Development Neurotrophin/TRK Signaling
miR-199a-5p Cancer Cell Death Hematological System Development
and Function
Wnt/b-catenin Signaling
miR-106a Cancer Gene Expression Nervous System Development
and Function
SAPK/JNK Signaling
miR-205 Cancer Gene Expression Tissue Morphology p53 Signaling
miR-197 Cancer Cellular Assembly and Organization Connective Tissue Development
and Function
GABA Receptor Signaling
miR-16 Cancer Cell Cycle Organismal Development TGF-b Signaling
miR-27a Cancer Cellular Growth and Proliferation Hematological System Development
and Function
PTEN Signaling
miR-142-5p Cancer Gene Expression Tissue Development Regulation of Actin-based Motility by
Rho
miR-512-3p Genetic Disorder Cell-to-Cell Signaling and Interaction Nervous System Development
and Function
Apoptosis Signaling
miR-148a Cancer Gene Expression Nervous System Development and Function Cell Cycle: G2/M DNA Damage
Checkpoint Regulation
miR-302b Cancer Gene Expression Tissue Development Cell Cycle: G1/S Checkpoint Regulation
miR-10a Cancer Gene Expression Organismal Development VEGF Signaling
miR-196a Cancer Cellular Growth and Proliferation Connective Tissue Development and Function Chemokine Signaling
miR-132 Cancer Gene Expression Nervous System Development and Function Wnt/b-catenin Signaling
The top pathway is indicated for each parameter.
doi:10.1371/journal.pone.0011780.t002
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transduction pathway and the CD44 protein, which is a cell-
surface glycoprotein involved in cell-cell interactions, cell adhesion
and migration, was also down-regulated in our data set (Figure 3).
A recent study showed that miR-200a could predict patient
survival in cervical cancer and functional studies suggest that it
may affect the metastatic potential of cervical cancer cells [21].
This miRNA is also down-regulated between our normal cervical
samples and the pre-neoplasic and neoplasic samples (p,0.012;
data not shown), suggesting that some of those miRNAs that we
found down-regulated from normal to cancer samples could be use
as prognostic markers.
miRNAs deregulated between normal cervix and pre-
neoplasic samples
Among the miRNAs that were down-regulated between normal
and pre-neoplasic cervical samples, but had increased expression
in cervical cancer samples, were miR-106a, miR-205, miR-197,
miR-16, miR-27a and miR-142-5p. Down-regulation of these
miRNAs in CIN I and CIN III samples suggested that they may
play an important role in cervical cell abnormal transformation by
HPV infection, but are not directly involved in progression to
malignant state since their expression is nearly restored to the
levels of normal cervical samples. Interestingly, miR-142-5p is
located in 17q23, which is in proximity to the t(8, 17) breakpoint in
B cell acute leukemia and also within the minimal amplicon in
breast cancer and near the FRA17B site, a target for HPV16
integration in cervical tumours [14]. We were able to predict
several important targets of miR-106a using miRanda, PicTar and
TargetScan, namely the microtubule-associated protein MAP7,
which is predominantly expressed in cells of epithelial origin and is
essential for cell polarization and differentiation, the early growth
response protein EGR2, the BCL2L2 protein, which is an anti-
apoptotic member of the BCL2 protein family, the mitogen-
activated protein kinase MAPK9, the oncogene MYCN, as well as
the tumour suppressor gene TP53INP. This may suggest that miR-
106a may play an important role during the initial stages of
atypical growth by targeting proteins involved in cell growth and
proliferation rather than being directly involved in cervical
carcinogenesis, depending on its cellular concentration. Our data
set suggests that miR-16 and miR-205 may have an oncogenic role
or at least they seem to promote abnormal cell growth in basal
epithelial cells since they are down-regulated in CINI and CINIII
compared with normal cervical tissue and are up-regulated in
cervical samples. In addition, they share putative targets, which
are involved in cell growth, migration and proliferation, namely
the vascular endothelial growth factor A (VEGFA) and the anti-
apoptotic protein BCL2. Also, miR-16 is deleted or down-
regulated in Chronic Lymphocytic Leukemia and miR-205 is
located in a chromosomal region, which is amplified in lung
cancer and is down-regulated in human prostate cancer. The miR-
27a and miR-197 showed expression patterns that go from down-
regulation between normal cervical tissues and CINI and CINIII
samples to slight up-regulation in cervical cancer. In breast cancer
cells miR-27a acts as an oncogene by targeting Myt-1, which
blocks cell cycle progression at G2-M and through regulation of Sp
proteins that have an important role in angiogenesis and growth of
cancer cells [36]. Our study suggests that miR-27a acts as an
oncogene, particularly in the early stages of cervical cell abnormal
transformation, because it targets the EGFR protein, the cyclin-
dependent kinases CD28 and CD44, the oncogenes KRAS and
MYCN, the MAPK7, the VEGFB and VGF. The expression
pattern of miR-197 is similar to that of miR-27a suggesting a
similar role. The miR-512-3p and miR-522* were up-regulated
between the normal cervical tissues and CINI and CINIII samples
and had normal expression in cervical carcinoma. The expression
pattern of miR-512-3p and its putative targets (Table S2) suggest
that this miRNA may play an important role in the development
of dysplasia in cervical tissues and is apparently less important
during cell invasion. Interestingly, the predictive targets of miR-
152-p includes mitogen-activated protein kinase kinases
MAP3K11 and MAP2K4, which activate the mitogen-activated
protein kinase pathway implicated in the development and
progression of many human cancers and the oncogene erbb4 and
the cell adhesion protein 4 CADM4 involved in cell-cell adhesion.
And also the autophagy TP53INP1 and TP53INP2 proteins [37].
Thus, depending on the cell state and miRNA level, miR-521-3p
may function as an oncogene or tumour suppressor and it may
Table 3. Comparison of miRNA expression profiles in cervical cancer studies published in the literature and the present study.
Lui et al. [15] Martinez et al. [17] Lee et al. [18] Wang et al. [20] Pereira et al.
Cervical cell lines Cervical cell lines Cervical tissues
Cervical
tissues
Cervical cell
lines Cervical tissues
miR-143 down down up down down
miR-145 down up down down
miR-21 up up up
miR-199a up down down
miR-203 up down down
miR-155 up up
miR-29a up down down
miR-146a up down up
miR-218 down up down down
miR-148a up up
miR-10a up
miR-196a up
The table only highlights miRNAs whose expression showed variability between the studies published in literature.
doi:10.1371/journal.pone.0011780.t003
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any predictive targets, but the miRNA expression pattern suggests
that this miRNA may also play a role in cervical abnormal
transformation.
miRNAs up-regulated in pre- and neoplasic samples
Several miRNAs, namely miR-148a, miR-302b, miR-10a, miR-
196a and miR-132 wereup-regulated in CINI samples. This increase
in expression was maintained in CINIII and cervical carcinoma. The
up-regulation of miR-10a and miR-132 confirmed the data from a
previous cervical carcinoma study wherethesemiRNAs were also up-
regulated [18]. Interestingly, miR-10a and miR-196a target
homeobox (HOX) genes, which are a family of transcription factors
that control developmental processes [38]. Up-regulation of these
transcriptional activators was initially thought to enhance oncogen-
esis, however, both loss and gain of HOX gene expression are related
to carcinogenesis [39]. The deregulation of HOX genes is associated
with both leukemia and solid malignancies [40–43], suggesting that
those two miRNAs contribute to cervical abnormal cell transforma-
tion and progression of cervical carcinoma through deregulation of
the HOX genes. Finally, miR-196a is located in the rare folate
sensitive fragile site FRA12A, the other two miRNAs that belong to
this group are miR-148a and miR-302b. These miRNAs target the
tumour suppressor genes, PTEN, TP53INP1 and TP53INP2,a n d
other proteins involved in cancer development and progression, such
a sB C L 2 L 2 ,E R B B 4 ,M A P K 9 ,M C L 1 ,M Y C N ,V E G F Aa n d
VEGFR1.
In conclusion, our study showed that natural miRNA expression
variability among cervical samples may complicate the use of
miRNA profiling in clinical diagnostics. The data provides an
explanation for the low consistency of cervical cancer miRNA
profiles available in the literature. We were able to minimize this
biological problem and were able to identify miRNAs whose
expression was significantly deregulated. Our strategy to use
multiple miRNA target prediction algorithms allowed us to
compile the largest list of putative targets of the miRNAs that
are differently expressed in cervical cancer. Genes involved in
cancer, cell death, cellular movement, cellular growth and
proliferation and gene expression processes were identified, which
to certain extent, validated our miRNA profiling data. Indeed,
several HOX genes were identified, which is in agreement with
data obtained in previous cervical carcinoma studies. In addition,
the well known oncogenes, MYCN, KRAS and VEGFs and the
tumour suppressors genes TP53INP and PTEN were identified as
targets of specific miRNAs. Therefore, our results increase the
understanding of the molecular basis of human cervical cancer
and confirm that aberrant expression of miRNA genes may be
important for the pathogenesis of this human neoplasia by
controlling or fine-tunning gene expression. The putative miRNA
targets provide new tools to better characterize cervical carcino-
genesis. In conclusion, our data supports a role for miRNAs in
cervical cancer and suggest that large scale miRNA profiling
studies should be carried out in order to obtain a robust miRNA
signature for this disease.
Materials and Methods
Ethics statement
At the time of initial diagnosis, all patients had provided consent
in the sense that their tumour samples could be used for
investigational purposes. Institutional approval from local research
ethical committee was obtained for the conduct of the study
(Comissa ˜o de E ´tica dos HUC - Hospitais da Universidade de
Coimbra). Data were analyzed anonymously. Patients provided
written consent so that their samples and clinical data could be
used for investigational purposes.
Tissue cervical samples
All tissue specimens were used with Hospital of the University of
Coimbra Ethical Committee approval and informed written
consent was obtained from patients. Each sample used in this
study was from a different patient of the Gynaecology Department
of the Hospital of the University of Coimbra. The specimens used
were: i) 4 pre-treatment squamous cell cervical carcinoma. ii)
Lesional epithelium frozen biopsies of 7 cases of high-grade SIL
(CINII, n=2 and CIN III, n=5) and 9 cases of low-grade SIL
(CIN I). In all cases the biopsy was composed of abnormal
epithelium as confirmed by cytology and histology. iii) 19 samples
were from normal cervix. Extracted tissue specimens were
immediately snap-frozen in liquid nitrogen and stored at 280uC
until the preparation of total RNA. The 19 normal cervix RNA
samples were pooled to obtain the normal cervix pooled sample.
miRNA microarray production
The miRNA microarrays used in this study were printed by the
National DNA-Microarray Facility located at the University of
Aveiro, Portugal. The arrays contained a total of 381 probes
spotted in quadruplicate. The 381 probes represent 281 known
human miRNAs, 49 mouse miRNAs, 14 rat miRNAs, 33
predicted human miRNAs and 4 control probes (Ambion). In
addition, we designed four oligonucleotides (,100 bp) containing
no homology to any known RNA sequence and generated their
corresponding synthetic RNAs by in vitro transcription using the
Ambion MEGAscriptH T7 Kit. Various amounts of these synthetic
RNAs were added to the human miRNA samples before analysis,
external controls.
Oligonucleotides probes were dissolved in 3XSSC buffer at a
concentration of 20 mM. and printed onto Nexterion E slides
(SCHOTT) using a MicroGrid II compact spotter. Printed
slides were further processed according to manufacture’s
recommendations.
RNA extraction and quantitation
Total RNA was extracted using the miRVana
TM miRNA
isolation kit (Ambion) according to the manufacture’s instructions.
RNA quantity and quality was assessed using the Nanodrop and
Agilent 2100 bioanalyzer systems, respectively. Samples with a
RIN number above 7 were used in the study.
miRNA microarray hybridization
Total RNA from test and reference (First Choice Human
Cervix RNA, Ambion) samples were labelled using the miRacULS
II miRNA labelling kit (Kreatech) according to the manufacture’s
instructions. Briefly, 3 mg of total RNA from test and reference
samples were incubated with Cy5- and Cy3-ULS, respectively for
15 min at 85uC. The labelled RNAs were purified to remove non-
reacted Cy-ULS followed by isolation of the labelled small RNA
fraction, to produce a fluorescently-labelled small RNA sample for
microarray analysis. Dye incorporation was monitored by UV-
visible spectroscopy. Hybridization was carried out in the home
made miRNA microarray at 42uC for 16h. Slides were washed
following the manufacture’s recommendations and immediately
scanned using an Agilent G2565AA microarray scanner.
Computational analysis of miRNA microarray data
Microarray images were analyzed using Quantarray v3.0
software (PerkinElmer). Cy3 and Cy5 median pixel intensity
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PLoS ONE | www.plosone.org 10 July 2010 | Volume 5 | Issue 7 | e11780values were background subtracted, normalized and subject to
further analysis. Data points were removed when intensity values
for both dyes were below 200% of background and absent calls
were removed before subsequent statistical analysis. A global
median normalization of cervical microarray data was applied
using BRB-ArrayTools v3.4.0 software. Cy5/Cy3 ratios were
obtained and log-transformed (base 2). Differentially expressed
miRNAs from each sample type were identified using the
Significance Analysis of Microarrays (SAM) software. One-way
ANOVA, Tukey’s Multiple Comparison Test, was performed to
identify miRNAs that demonstrated statistically significant differ-
entially expression between, normal cervix, CIN I, CIN III and
cervical squamous cell carcinoma.
Microarray Data Submission
Microarray data submission for human arrays is MIAME
compliant. The raw data has been submitted in Gene Expression
Omnibus (GEO) database and has been given the following
accession numbers: GSE19611; GPL7534; GSM489127–
GSM489169.
Taqman miRNA quantitative real-time Polymerase Chain
Reaction Analysis
Quantification of microRNA expression was carried out using
TaqMan MicroRNA Assay kits according to manufacturer’s
protocol (Applied Biosystems, Foster City, CA, USA). Prefabri-
cated TaqMan MicroRNA Assays were applied for the investiga-
tion of hsa-miR-143, hsa-miR-197, has-miR-27a, has-miR-10a
and has-miR-148a. We also quantified transcripts of U6 small
RNA (RNU6B) as an endogenous control for normalizing the
levels of target miRNA. RNU6B is a widely used endogenous
reference RNA in miRNA quantification experiment because
RNU6B is not regulated under the experimental conditions and
shows a constant level of expression and similar abundance to the
target miRNA. CDNA was generated using the Taqman
MicroRNA Reverse Transcription (RT) Kit according to the
manufacturer’s instructions. Reverse transcriptase reactions con-
tained 10 ng of total RNA as the template, 3 mL5 6RT primer,
1.5 mL1 0 6 RT buffer, 0.15 mL 100 mM dNTPs, 1 mL Multi-
Scribe reverse transcriptase, 0.19 mL RNase Inhibitor, and
4.16 mL nuclease – free water. The 15 mL reactions were mixed
and incubated for 30 minutes at 16uC, 30 minutes at 42uC,
5 minutes at 85uC, and then held at 4uC. All reverse transcriptions
and no-template controls were run at the same time following the
RT step. Real-time Quantitative PCR was carried out using the
ABI Prism 7500 Sequence Detector System (Applied Biosystems).
The 20-mL PCR reactions contained 1.33 mL RT product, 10 mL
TaqManH Universal PCR Master Mix, No AmpEraseH UNG,
7.67 ml nuclease – free water and 1 mLo f2 0 6MicroRNA Assay.
Reactions were incubated in a 96-well optical plate and the cycling
began with template denaturation and hot start Taq activation at
95uC for 10 minutes, followed by 40 cycles of 95uC for 15 seconds
and 60uC for one minute. The threshold cycle data (CT) and
baselines were determined using auto settings. All assays including
no template controls were done in triplicate. Relative quantifica-
tion of miRNA expression was calculated by the 2
2DDCT method
[44], where control sample was the normal cervix reference
(Ambion).
Supporting Information
Table S1 Twenty-one miRNAs differentially expressed in
clinical cervical samples.
Found at: doi:10.1371/journal.pone.0011780.s001 (0.07 MB
DOC)
Table S2 Predictive gene targets of 21 miRNAs differentially
expressed in clinical cervical samples.
Found at: doi:10.1371/journal.pone.0011780.s002 (0.37 MB
XLS)
Table S3 Ingenuity analysis of miRNA predictive target genes.
The top three pathways are indicated for each parameter.
Pathways found more that 3 times are indicated in bold.
Found at: doi:10.1371/journal.pone.0011780.s003 (0.10 MB
DOC)
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